Fariza A. Cheldieva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fariza A. Cheldieva has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
25 shared publications - Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
19 shared publications - Anastasiia A. Shumilova
V.A. Nasonova Research Institute of Rheumatology
12 shared publications - Mariya V. Cherkasova
V.A. Nasonova Research Institute of Rheumatology
11 shared publications - Evgenii L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
8 shared publications - Kamila S. Nurbaeva
V.A. Nasonova Research Institute of Rheumatology, Moscow 115522, Russia
8 shared publications
Latest Publications
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3)
Russian-language version of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS)
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3)
Russian-language version of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS)
- Open Access
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 32-38
Assessment of antiphospholipid antibodies using enzyme-linked immunosorbent assay and chemiluminescent method
Antiphospholipid antibodies (aPL) are a sign of acquired thrombophilia and are associated with recurrent thrombosis and obstetric pathology. According 2006 classification criteria, serological markers of antiphospholipid syndrome (APS) include lupus anticoagulant, moderate and high levels of antibodies to cardiolipin (aСL) and â2-glycoprotein 1 (anti- â2-GP1) IgG and IgM. The task of standardizing aPL values remains unresolved, leading to variability in results.Objective: to evaluate the comparability of IgG/IgM aCL and IgG/IgM anti- â2-GP1 measurement results using enzyme-linked immunosorbent assay (ELISA) and chemiluminescence (CLU) tests.Material and methods. Peripheral blood from 192 patients (147 women and 45 men) was analyzed, 55 patients (29%) had primary APS, 12 (6%) had probable APS, 61 (32%) had systemic lupus erythematosus (SLE) and APS, and 64 (33%) had SLE without APS. IgG/IgM aCL and IgG/IgM anti- â2-GP1 were determined in all participants by ELISA. By CLU method IgG/IgM aCL were analyzed in 192 patients and IgG/IgM anti- â2-GP1 in 191 patients.Results and discussion. The evaluation of the comparability of the results of ELISA and CLU revealed considerable discrepancies in the positive tests. Thus, in 16% of cases, a discrepancy was found in the levels of IgG aCL and IgM aCL by both methods (n=30 and n=31, respectively), in 18% in the level of IgG anti- â2-GP1 (n=34) and in 15% in the level of IgM anti- â2-GP1 (n=28).These discrepancies were to a greater extent associated with a more frequent detection of aPL in CLU when their values were negative in ELISA , indicating the greater information capacity of the CLU method.However, a small number of patients were positive for aPL in ELISA but negative in CLU: 5 with IgG aCL, 4 with IgM aCL, 6 with IgG anti-â2-GP1, and 2 with IgM anti- â2-GP1 .Conclusion. CLU is shown to be a more informative method for determining IgG aCL and IgG anti- â2-GP1 than ELISA (p<0.05).
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 32-38
Open AccessAssessment of antiphospholipid antibodies using enzyme-linked immunosorbent assay and chemiluminescent method
Antiphospholipid antibodies (aPL) are a sign of acquired thrombophilia and are associated with recurrent thrombosis and obstetric pathology. According 2006 classification criteria, serological markers of antiphospholipid syndrome (APS) include lupus anticoagulant, moderate and high levels of antibodies to cardiolipin (aСL) and â2-glycoprotein 1 (anti- â2-GP1) IgG and IgM. The task of standardizing aPL values remains unresolved, leading to variability in results.Objective: to evaluate the comparability of IgG/IgM aCL and IgG/IgM anti- â2-GP1 measurement results using enzyme-linked immunosorbent assay (ELISA) and chemiluminescence (CLU) tests.Material and methods. Peripheral blood from 192 patients (147 women and 45 men) was analyzed, 55 patients (29%) had primary APS, 12 (6%) had probable APS, 61 (32%) had systemic lupus erythematosus (SLE) and APS, and 64 (33%) had SLE without APS. IgG/IgM aCL and IgG/IgM anti- â2-GP1 were determined in all participants by ELISA. By CLU method IgG/IgM aCL were analyzed in 192 patients and IgG/IgM anti- â2-GP1 in 191 patients.Results and discussion. The evaluation of the comparability of the results of ELISA and CLU revealed considerable discrepancies in the positive tests. Thus, in 16% of cases, a discrepancy was found in the levels of IgG aCL and IgM aCL by both methods (n=30 and n=31, respectively), in 18% in the level of IgG anti- â2-GP1 (n=34) and in 15% in the level of IgM anti- â2-GP1 (n=28).These discrepancies were to a greater extent associated with a more frequent detection of aPL in CLU when their values were negative in ELISA , indicating the greater information capacity of the CLU method.However, a small number of patients were positive for aPL in ELISA but negative in CLU: 5 with IgG aCL, 4 with IgM aCL, 6 with IgG anti-â2-GP1, and 2 with IgM anti- â2-GP1 .Conclusion. CLU is shown to be a more informative method for determining IgG aCL and IgG anti- â2-GP1 than ELISA (p<0.05).
- Open Access
- 1 November 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (5) , 564-569
Systemic lupus erythematosus and herpes zoster: Difficulties of curation (description of clinical observations)
Patients with systemic lupus erythematosus (SLE) have an increased risk of developing herpes zoster (HZ). Vaccination difficulties arise in these patients due to possible interactions with the therapy used with glucocorticoids, disease-modifying antirheumatic drugs and biologic disease-modifying anti-rheumatic drugs. The description of two clinical observations of patients with SLE, who developed severe HZ against the background of active SLE and therapy with immunosuppressive drugs, is given. The issue of the need for vaccination in Russia against varicella zoster virus of patients on immunosuppressive therapy is discussed.
- 1 November 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (5) , 564-569
Open AccessSystemic lupus erythematosus and herpes zoster: Difficulties of curation (description of clinical observations)
Patients with systemic lupus erythematosus (SLE) have an increased risk of developing herpes zoster (HZ). Vaccination difficulties arise in these patients due to possible interactions with the therapy used with glucocorticoids, disease-modifying antirheumatic drugs and biologic disease-modifying anti-rheumatic drugs. The description of two clinical observations of patients with SLE, who developed severe HZ against the background of active SLE and therapy with immunosuppressive drugs, is given. The issue of the need for vaccination in Russia against varicella zoster virus of patients on immunosuppressive therapy is discussed.
- Open Access
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 408–417
Thrombotic antiphospholipid syndrome: Recurrent thromboses
Thrombotic antiphospholipid syndrome (APS) is a condition affecting young people in whom a thromboembolic event occurs in the presence of circulating antiphospholipid antibodies (aPL).The aim of this study was the evaluation of the incidence of recurrent thrombosis and its risk factors in antiphospholipid syndrome.Material and methods. The retrospective study included 98 patients with aPL who were followed up at the institute from 2014 to 2023, of whom 66 (67%) were women and 32 (33%) were men. Of the 98 patients with aPL, 48 (49%) had a diagnosis of systemic lupus erythematosus (SLE). Antiphospholipid antibodies (aPL), including antibodies to cardiolipin (IgG/IgM aCL), antibodies to ß2-glycoprotein 1 (IgG/IgM aß2GP1), antibodies to ß2-glycoprotein IgG against domain 1 (IgG aß2GP1-D1), antibodies to phosphatidylserine/prothrombin complex (IgG/ IgM aPS/PT) and other thrombotic risk factors. aPL was assessed by enzyme-linked immunosorbent assay (ELISA) and chemoluminescence assay (CHLA).Results. Thrombosis recurrence was reported in 62 (63%) of 98 patients, and 36 (35%) did not. The main cause of recurrent thrombosis was treatment with direct oral anticoagulants (DOACs). 24 (38.7%) of 62 patients with recurrent thrombosis were treated with DOACs, the duration of which ranged from 6 to 24 months. The next most common cause of recurrent thrombosis was the lack of continuous anticoagulant therapy in 20 (32.5%) of the patients. In 17 (27.4%) of the patients, the recurrence occurred while they were still taking warfarin. In 10 (41.7%) of the 24 patients, the recurrent thrombosis was arterial in origin. This was associated with recurrent cerebral circulation problems. The level of positivity did not matter, but all had triple IgG aPL positivity. 5 had lupus anticoagulant (LA) at the onset of the disease before anticoagulant use. IgG aPS/PT was most important in association with recurring thrombosis in the ELISA: 45 (72.6%) of 62 patients with recurring thrombosis were positive for IgG aPS/PT, compared with 19 (52.8%) of 36 patients without recurring thrombosis. The detection of all aPL was more frequent in CHMA than in ELISA. However, the definition of aPL in ELISA is recommended according to the latest classification criteria. Triple IgG positivity for aCL of IgG aß2GP1, IgG aß2GP1-D1 and CHMA remained a risk factor for recurrent thrombosis and increased the risk of recurrence more than threefold. Obesity was a risk factor for recurrent thrombosis, with a 5-fold increased risk of recurrent thrombosis in obese compared to non-obese patients (p=0.01).Conclusions. Recurrent thrombosis in APS is largely associated with IgG aCL, IgG aß2GP1, IgG aß2GP1-D1, IgG aPS/PT. Triple IgG aPL positivity in any combination significantly increased recurrent thrombosis risk.The presence of any type of aPL IgG in both ELISA and CHLA influenced the recurrence rate of thrombosis in APS.Obesity was a significant risk factor for recurrent thrombosis.
- 2 September 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (4) , 408–417
Open AccessThrombotic antiphospholipid syndrome: Recurrent thromboses
Thrombotic antiphospholipid syndrome (APS) is a condition affecting young people in whom a thromboembolic event occurs in the presence of circulating antiphospholipid antibodies (aPL).The aim of this study was the evaluation of the incidence of recurrent thrombosis and its risk factors in antiphospholipid syndrome.Material and methods. The retrospective study included 98 patients with aPL who were followed up at the institute from 2014 to 2023, of whom 66 (67%) were women and 32 (33%) were men. Of the 98 patients with aPL, 48 (49%) had a diagnosis of systemic lupus erythematosus (SLE). Antiphospholipid antibodies (aPL), including antibodies to cardiolipin (IgG/IgM aCL), antibodies to ß2-glycoprotein 1 (IgG/IgM aß2GP1), antibodies to ß2-glycoprotein IgG against domain 1 (IgG aß2GP1-D1), antibodies to phosphatidylserine/prothrombin complex (IgG/ IgM aPS/PT) and other thrombotic risk factors. aPL was assessed by enzyme-linked immunosorbent assay (ELISA) and chemoluminescence assay (CHLA).Results. Thrombosis recurrence was reported in 62 (63%) of 98 patients, and 36 (35%) did not. The main cause of recurrent thrombosis was treatment with direct oral anticoagulants (DOACs). 24 (38.7%) of 62 patients with recurrent thrombosis were treated with DOACs, the duration of which ranged from 6 to 24 months. The next most common cause of recurrent thrombosis was the lack of continuous anticoagulant therapy in 20 (32.5%) of the patients. In 17 (27.4%) of the patients, the recurrence occurred while they were still taking warfarin. In 10 (41.7%) of the 24 patients, the recurrent thrombosis was arterial in origin. This was associated with recurrent cerebral circulation problems. The level of positivity did not matter, but all had triple IgG aPL positivity. 5 had lupus anticoagulant (LA) at the onset of the disease before anticoagulant use. IgG aPS/PT was most important in association with recurring thrombosis in the ELISA: 45 (72.6%) of 62 patients with recurring thrombosis were positive for IgG aPS/PT, compared with 19 (52.8%) of 36 patients without recurring thrombosis. The detection of all aPL was more frequent in CHMA than in ELISA. However, the definition of aPL in ELISA is recommended according to the latest classification criteria. Triple IgG positivity for aCL of IgG aß2GP1, IgG aß2GP1-D1 and CHMA remained a risk factor for recurrent thrombosis and increased the risk of recurrence more than threefold. Obesity was a risk factor for recurrent thrombosis, with a 5-fold increased risk of recurrent thrombosis in obese compared to non-obese patients (p=0.01).Conclusions. Recurrent thrombosis in APS is largely associated with IgG aCL, IgG aß2GP1, IgG aß2GP1-D1, IgG aPS/PT. Triple IgG aPL positivity in any combination significantly increased recurrent thrombosis risk.The presence of any type of aPL IgG in both ELISA and CHLA influenced the recurrence rate of thrombosis in APS.Obesity was a significant risk factor for recurrent thrombosis.
- Open Access
- 27 June 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (3) , 325-330
Pregnancy and its outcome in antiphospholipid syndrome after acute cerebral circulatory failure (clinical case study)
Obstetric pathology (pregnancy loss at different gestational ages; premature delivery of morphologically normal foetus due to pre-/eclampsia or placental insufficiency), along with thrombotic complications are the main clinical manifestations of antiphospholipid syndrome (APS). Among arterial thromboses in APS, cerebral vascular thromboses in the form of strokes or transient ischaemic attacks. Patients with APS have a well known increased risk of thrombosis associated with pregnancy or conditions accompanied by hyperestrogenemia. More than half of thrombotic complications in women with APS occur during gestation or hyperestrogenemia. Most studies of pregnancy in APS have focused on women with recurrent fetal loss, and data on pregnancy outcomes in patients with other clinical phenotypes of APS, such as thrombotic APS, are limited. We present a case report of a patient with reliable thrombotic APS (with recurrent ischaemic cerebral circulatory disorders) and highly positive levels of antiphosphrolipid antibodies with a favourable pregnancy outcome.
- 27 June 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (3) , 325-330
Open AccessPregnancy and its outcome in antiphospholipid syndrome after acute cerebral circulatory failure (clinical case study)
Obstetric pathology (pregnancy loss at different gestational ages; premature delivery of morphologically normal foetus due to pre-/eclampsia or placental insufficiency), along with thrombotic complications are the main clinical manifestations of antiphospholipid syndrome (APS). Among arterial thromboses in APS, cerebral vascular thromboses in the form of strokes or transient ischaemic attacks. Patients with APS have a well known increased risk of thrombosis associated with pregnancy or conditions accompanied by hyperestrogenemia. More than half of thrombotic complications in women with APS occur during gestation or hyperestrogenemia. Most studies of pregnancy in APS have focused on women with recurrent fetal loss, and data on pregnancy outcomes in patients with other clinical phenotypes of APS, such as thrombotic APS, are limited. We present a case report of a patient with reliable thrombotic APS (with recurrent ischaemic cerebral circulatory disorders) and highly positive levels of antiphosphrolipid antibodies with a favourable pregnancy outcome.
- Open Access
- 29 April 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (2) , 203-215
Indexes of skin activity and damage in patients with systemic lupus erythematosus – CLASI and R-CLASI
Introduction. Cutaneous Lupus Disease Area and Severity Index (CLASI) and its modified version, the Revised Cutaneous Lupus Erythematosus Disease Areas and Severity Index (R-CLASI) are tools for quantifying skin and mucosal lesions in patients with both cutaneous lupus erythematosus and its systemic variant. Evaluation of the scales of activity and skin damage in systemic lupus erythematosus (SLE) is associated with the need to stratify their quantitative characteristics. The Cutaneous Lupus Disease Area and Severity Index (CLASI) and its modified version the Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (R-CLASI) are a tool for quantifying skin and mucosal lesions in patients with both cutaneous lupus erythematosus (CLE) and its system version.Objective. To validate the indexes of objective assessment of skin activity and damage CLASI and R-CLASI in the Russian cohort of patients with systemic lupus erythematosus and compare it with dermatological assessments of the quality of life.Material and methods. The study included 55 patients with SLE with various types of skin and mucosal lesions, the median age was 30.0 [26.0; 40.0] years, the duration of the disease was 7.0 [3.0; 14.0] years. To assess the active (reversible) lesion and irreversible skin damage, the CLASI and R-CLASI indexes were used, for the general assessment of activity and damage in SLE, the SLEDAI-2K and SLICC/ACR DI were used.Results. The most common variant of skin lesions in patients with SLE is acute cutaneous lupus erythematosus (ACLE) – 45%, as well as alopecia, which occurs in 62% of cases. The median activity index for CLASI was 5.0 [2.0; 11.0], and R-CLASI was 7.0 [3.0; 18.0]; the median damage index for CLASI was 5.0 [2.0; 11.0], and R-CLASI was 2.0 [0.0; 7.0]. A significant relationship was revealed between the medians of CLASI and R-CLASI scores depending on the degree of activity according to SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) and the damage Index (DI) in SLE (SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) when recalculating these indexes only for skin and mucous lesions. According to the ROC analysis, the CLASI and R-CLASI skin activity and damage indices showed high sensitivity (CLASI activity index – 98%, R-CLASI – 93%, CLASI and R-CLASI damage index – 91%) and specificity (CLASI activity index – 64%, R-CLASI – 71%, CLASI and R-CLASI damage index – 86%).Conclusion. To assess the severity of skin and mucosal lesions in patients with SLE in the Russian Federation, it is reasonable to use the CLASI and R-CLASI indices. The CLASI and R-CLASI indices reflect the level of activity and severity of skin lesions, with higher values of these indices indicating more severe skin lesions and a significant impact on the overall well-being of SLE patients. Patients with high values of these indices often experience feelings of embarrassment, discomfort, difficulty in performing daily tasks, and limitations in social life. To assess the severity of skin and mucous lesions in patients with SLE in the Russian Federation, it is advisable to use the CLASI and R-CLASI indexes.
- 29 April 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (2) , 203-215
Open AccessIndexes of skin activity and damage in patients with systemic lupus erythematosus – CLASI and R-CLASI
Introduction. Cutaneous Lupus Disease Area and Severity Index (CLASI) and its modified version, the Revised Cutaneous Lupus Erythematosus Disease Areas and Severity Index (R-CLASI) are tools for quantifying skin and mucosal lesions in patients with both cutaneous lupus erythematosus and its systemic variant. Evaluation of the scales of activity and skin damage in systemic lupus erythematosus (SLE) is associated with the need to stratify their quantitative characteristics. The Cutaneous Lupus Disease Area and Severity Index (CLASI) and its modified version the Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (R-CLASI) are a tool for quantifying skin and mucosal lesions in patients with both cutaneous lupus erythematosus (CLE) and its system version.Objective. To validate the indexes of objective assessment of skin activity and damage CLASI and R-CLASI in the Russian cohort of patients with systemic lupus erythematosus and compare it with dermatological assessments of the quality of life.Material and methods. The study included 55 patients with SLE with various types of skin and mucosal lesions, the median age was 30.0 [26.0; 40.0] years, the duration of the disease was 7.0 [3.0; 14.0] years. To assess the active (reversible) lesion and irreversible skin damage, the CLASI and R-CLASI indexes were used, for the general assessment of activity and damage in SLE, the SLEDAI-2K and SLICC/ACR DI were used.Results. The most common variant of skin lesions in patients with SLE is acute cutaneous lupus erythematosus (ACLE) – 45%, as well as alopecia, which occurs in 62% of cases. The median activity index for CLASI was 5.0 [2.0; 11.0], and R-CLASI was 7.0 [3.0; 18.0]; the median damage index for CLASI was 5.0 [2.0; 11.0], and R-CLASI was 2.0 [0.0; 7.0]. A significant relationship was revealed between the medians of CLASI and R-CLASI scores depending on the degree of activity according to SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) and the damage Index (DI) in SLE (SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) when recalculating these indexes only for skin and mucous lesions. According to the ROC analysis, the CLASI and R-CLASI skin activity and damage indices showed high sensitivity (CLASI activity index – 98%, R-CLASI – 93%, CLASI and R-CLASI damage index – 91%) and specificity (CLASI activity index – 64%, R-CLASI – 71%, CLASI and R-CLASI damage index – 86%).Conclusion. To assess the severity of skin and mucosal lesions in patients with SLE in the Russian Federation, it is reasonable to use the CLASI and R-CLASI indices. The CLASI and R-CLASI indices reflect the level of activity and severity of skin lesions, with higher values of these indices indicating more severe skin lesions and a significant impact on the overall well-being of SLE patients. Patients with high values of these indices often experience feelings of embarrassment, discomfort, difficulty in performing daily tasks, and limitations in social life. To assess the severity of skin and mucous lesions in patients with SLE in the Russian Federation, it is advisable to use the CLASI and R-CLASI indexes.
- Open Access
- 28 April 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (2) , 176-185
Mental disorders in antiphospholipid syndrome patients: association with clinical and immunological manifestations of the disease
The aim of this work is to clarify the association between the clinical and psychopathological features of mental disorders (MD) and the clinical and immunological features of antiphospholipid syndrome (APS).Material and methods. The study included 107 patients (34 (31.8%) men and 73 (68.2%) women) aged 18 to 69 years (40.6±10.4 years (M±SD)), 54 (50.5%) – with primary APS (PAPS), established according to the international criteria of 2006 and 53 (49.5%) patients – with reliable diagnosis of systemic lupus erythematosus (SLE), according to the European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ ACR) 2019 criteria, with a secondary APS. Risk of thrombosis in APS was assessed by the GAPSS (Global Anti-Phospholipid Syndrome Score). MD were diagnosed by a psychiatrist in accordance with 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) and Diagnostic and Statistical Manual of mental disorders, 5th edition (DSM-5).Results. Mental disorders are detected in the vast majority of patients with APS (98 (91.6%)), predominantly in anxiety-depressive spectrum disorders (ADSD; 90 (84.1%)). Depressive disorders are not associated with a high risk of thrombosis according to the GAPSS, but more severe variants of depression are more common in patients with high anti-β2 -glycoprotein I (anti-β2 GP1) and low/moderate anti cardiolipin (aCL) antibodies. Anxiety disorders were diagnosed only in patients with a high risk of thrombosis according to GAPSS, high aCL and IgG anti-β2 GP1. Schizotypal disorder was identified only in patients with a high risk of thrombosis and positive anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) regardless of class, and also more often in patients with high IgG anti-β2 GP1. Epilepsy was observed only in patients with positive aPS/PT, regardless of class. Cognitive impairment (CI), mostly mild and moderate, was found in the vast majority of patients with APS (102 (95.3%)). Dementia was detected in 7 (6.5%) patients, and only in those who had acute or transient cerebrovascular accident. When compared with the general population, dementia developed at an earlier age (up to 65 years). For patients with a high risk of thrombosis, moderate CI is more typical. CI and their severity are not associated with the duration of APS, but are associated with positivity for IgG aPS/PT, acute or transient cerebrovascular accident and the duration of comorbid ADSD.Conclusion. A high frequency of MD in patients with APS revealed. Associations of MD with clinical and immunological manifestations of APS were determined. CI in patients with APS is heterogeneous and are associated with both clinical and immunological manifestations of APS and MD. Identification of CI and determination of their characteristics should be confirmed by clinical, psychopathological and pathopsychological methods in order to personalize their correction within the partnership model of care.
- 28 April 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (2) , 176-185
Open AccessMental disorders in antiphospholipid syndrome patients: association with clinical and immunological manifestations of the disease
The aim of this work is to clarify the association between the clinical and psychopathological features of mental disorders (MD) and the clinical and immunological features of antiphospholipid syndrome (APS).Material and methods. The study included 107 patients (34 (31.8%) men and 73 (68.2%) women) aged 18 to 69 years (40.6±10.4 years (M±SD)), 54 (50.5%) – with primary APS (PAPS), established according to the international criteria of 2006 and 53 (49.5%) patients – with reliable diagnosis of systemic lupus erythematosus (SLE), according to the European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ ACR) 2019 criteria, with a secondary APS. Risk of thrombosis in APS was assessed by the GAPSS (Global Anti-Phospholipid Syndrome Score). MD were diagnosed by a psychiatrist in accordance with 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) and Diagnostic and Statistical Manual of mental disorders, 5th edition (DSM-5).Results. Mental disorders are detected in the vast majority of patients with APS (98 (91.6%)), predominantly in anxiety-depressive spectrum disorders (ADSD; 90 (84.1%)). Depressive disorders are not associated with a high risk of thrombosis according to the GAPSS, but more severe variants of depression are more common in patients with high anti-β2 -glycoprotein I (anti-β2 GP1) and low/moderate anti cardiolipin (aCL) antibodies. Anxiety disorders were diagnosed only in patients with a high risk of thrombosis according to GAPSS, high aCL and IgG anti-β2 GP1. Schizotypal disorder was identified only in patients with a high risk of thrombosis and positive anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) regardless of class, and also more often in patients with high IgG anti-β2 GP1. Epilepsy was observed only in patients with positive aPS/PT, regardless of class. Cognitive impairment (CI), mostly mild and moderate, was found in the vast majority of patients with APS (102 (95.3%)). Dementia was detected in 7 (6.5%) patients, and only in those who had acute or transient cerebrovascular accident. When compared with the general population, dementia developed at an earlier age (up to 65 years). For patients with a high risk of thrombosis, moderate CI is more typical. CI and their severity are not associated with the duration of APS, but are associated with positivity for IgG aPS/PT, acute or transient cerebrovascular accident and the duration of comorbid ADSD.Conclusion. A high frequency of MD in patients with APS revealed. Associations of MD with clinical and immunological manifestations of APS were determined. CI in patients with APS is heterogeneous and are associated with both clinical and immunological manifestations of APS and MD. Identification of CI and determination of their characteristics should be confirmed by clinical, psychopathological and pathopsychological methods in order to personalize their correction within the partnership model of care.
- Open Access
- 1 December 2023
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 513 (1) , 360
Erratum to: Global Antiphospholipid Syndrome Score (GAPSS) in Patients with Systemic Lupus Erythematosus
An Erratum to this paper has been published: https://doi.org/10.1134/S1607672923050046
- 1 December 2023
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 513 (1) , 360
Open AccessErratum to: Global Antiphospholipid Syndrome Score (GAPSS) in Patients with Systemic Lupus Erythematosus
An Erratum to this paper has been published: https://doi.org/10.1134/S1607672923050046
- Open Access
- 18 October 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (5) , 107-111
Adaptation of the Russian version of the activity index of systemic lupus erythematosus EASY-BILAG
Assessment of systemic lupus erythematosus (SLE) activity is important to determine the efficacy of treatment and to decide on further therapy. Russian-language versions of activity indices are needed to meet the needs of Russian-speaking patients and clinicians and to facilitate the use of these tools in clinical practice. An important step in this direction is the adaptation of the EASY-BILAG index, which is used to more accurately assess disease activity and select appropriate therapy in patients with SLE.
- 18 October 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (5) , 107-111
Open AccessAdaptation of the Russian version of the activity index of systemic lupus erythematosus EASY-BILAG
Assessment of systemic lupus erythematosus (SLE) activity is important to determine the efficacy of treatment and to decide on further therapy. Russian-language versions of activity indices are needed to meet the needs of Russian-speaking patients and clinicians and to facilitate the use of these tools in clinical practice. An important step in this direction is the adaptation of the EASY-BILAG index, which is used to more accurately assess disease activity and select appropriate therapy in patients with SLE.
- Open Access
- 16 October 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (5) , 15-21
Efficacy and safety of long-term use of low molecular weight heparins in patients with systemic lupus erythematosus and antiphospholipid syndrome
To date, the management of patients with antiphospholipid syndrome (APS) with ineffectiveness and/or intolerance to vitamin K antagonists and direct oral anticoagulants remains controversial. One of the treatment strategies is the administration of low molecular weight heparins (LMWH) over a long period of time. Objective: to evaluate the efefficacy and safety of long-term treatment with LMWH in patients with APS. Material and methods. The study included 15 patients (13 women and 2 men) with APS. In 2 of them APS was isolated, in 12 it was combined with systemic lupus erythematosus (SLE), and in 1 – with SLE and psoriatic arthritis. The mean age of patients was 44 ± 12 years, and the mean duration of disease was 12 [6; 18] years. All patients were repeatedly examined in the V. A. Nasonova Research Institute of Rheumatology during hospitalizations and continued outpatient care in the clinical diagnostic center of the Institute. Results and discussion. Ten (67 %) patients received nadroparin, 5 (33 %) patients received enoxaparin. The median duration of therapy was 4 [1; 10] years. Indications for the use of LMWH were inefficacy and intolerance of oral anticoagulants (n = 12, 100 %) and vascular involvement such as thromboangiitis obliterans with the development of chronic arterial insufficiency, ulcers and necrosis of the toes (n = 6, 40 %). During therapy, 13 (86 %) of 15 patients showed clinical improvement: healing of ulcers and necrosis, reduction in the stage of arterial insufficiency, recanalization of venous blood clots. During the entire treatment period with LMWH, one patient experienced a relapse of thrombosis due to an insufficient dose of the drug. No hemorrhagic complications occurred in any case. Other adverse events, including elevated liver aminotransferases, osteoporosis, and thrombocytopenia, were also not observed. Conclusion. The results obtained suggest that long-term therapy with LMWH may be safe and effective in patients with APS.
- 16 October 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (5) , 15-21
Open AccessEfficacy and safety of long-term use of low molecular weight heparins in patients with systemic lupus erythematosus and antiphospholipid syndrome
To date, the management of patients with antiphospholipid syndrome (APS) with ineffectiveness and/or intolerance to vitamin K antagonists and direct oral anticoagulants remains controversial. One of the treatment strategies is the administration of low molecular weight heparins (LMWH) over a long period of time. Objective: to evaluate the efefficacy and safety of long-term treatment with LMWH in patients with APS. Material and methods. The study included 15 patients (13 women and 2 men) with APS. In 2 of them APS was isolated, in 12 it was combined with systemic lupus erythematosus (SLE), and in 1 – with SLE and psoriatic arthritis. The mean age of patients was 44 ± 12 years, and the mean duration of disease was 12 [6; 18] years. All patients were repeatedly examined in the V. A. Nasonova Research Institute of Rheumatology during hospitalizations and continued outpatient care in the clinical diagnostic center of the Institute. Results and discussion. Ten (67 %) patients received nadroparin, 5 (33 %) patients received enoxaparin. The median duration of therapy was 4 [1; 10] years. Indications for the use of LMWH were inefficacy and intolerance of oral anticoagulants (n = 12, 100 %) and vascular involvement such as thromboangiitis obliterans with the development of chronic arterial insufficiency, ulcers and necrosis of the toes (n = 6, 40 %). During therapy, 13 (86 %) of 15 patients showed clinical improvement: healing of ulcers and necrosis, reduction in the stage of arterial insufficiency, recanalization of venous blood clots. During the entire treatment period with LMWH, one patient experienced a relapse of thrombosis due to an insufficient dose of the drug. No hemorrhagic complications occurred in any case. Other adverse events, including elevated liver aminotransferases, osteoporosis, and thrombocytopenia, were also not observed. Conclusion. The results obtained suggest that long-term therapy with LMWH may be safe and effective in patients with APS.